Literature DB >> 27741367

Impact of smoking reduced nicotine content cigarettes on sensitivity to cigarette price: further results from a multi-site clinical trial.

Tracy T Smith1, Rachel N Cassidy2, Jennifer W Tidey2, Xianghua Luo3, Chap T Le3, Dorothy K Hatsukami4, Eric C Donny5.   

Abstract

AIMS: To assess the impact of a reduction in the nicotine content of cigarettes on estimated consumption of reduced nicotine cigarettes and usual brand cigarettes at a variety of hypothetical prices.
DESIGN: Double-blind study with participants assigned randomly to receive cigarettes for 6 weeks that were either usual brand or an investigational cigarette with one of five nicotine contents.
SETTING: Ten sites across the United States. PARTICIPANTS: A total of 839 eligible adult smokers randomized from 2013 to 2014. INTERVENTION AND COMPARATOR: Participants received their usual brand or an investigational cigarette with one of five nicotine contents: 15.8 (primary control), 5.2, 2.4, 1.3, or 0.4 mg/g. MEASUREMENTS: The Cigarette Purchase Task was completed at baseline and at the week 6 post-randomization visit.
FINDINGS: Compared with normal nicotine content controls, the lowest nicotine content (0.4 mg/g) reduced the number of study cigarettes participants estimated they would smoke at a range of prices [mean reduction relative to 15.8 mg/g at a price of $4.00/pack: 9.50, 95% confidence interval (CI) = 6.81,12.19]. The lowest nicotine content also reduced the maximum amount of money allocated to study cigarettes and the price at which participants reported they would stop buying study cigarettes [median reduction relative to 15.8 mg/g, 95% CI = $8.21 (4.27,12.15) per day and $0.44 (0.17,0.71) per cigarette, respectively]. A reduction in nicotine content to the lowest level also reduced the maximum amount of money allocated to usual brand cigarettes (median reduction relative to 15.8 mg/g: $4.39 per day, 95% CI = 1.88,6.90).
CONCLUSIONS: In current smokers, a reduction in nicotine content may reduce cigarette consumption, reduce the reinforcement value of cigarettes and increase cessation if reduced nicotine content cigarettes were the only cigarette available for purchase.
© 2016 Society for the Study of Addiction.

Entities:  

Keywords:  End game; harm reduction; nicotine; public policy; smoking; taxation

Mesh:

Substances:

Year:  2016        PMID: 27741367      PMCID: PMC5233558          DOI: 10.1111/add.13636

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  23 in total

Review 1.  Deconstructing relative reinforcing efficacy and situating the measures of pharmacological reinforcement with behavioral economics: a theoretical proposal.

Authors:  W K Bickel; L A Marsch; M E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

2.  Modeling drug consumption in the clinic using simulation procedures: demand for heroin and cigarettes in opioid-dependent outpatients.

Authors:  E A Jacobs; W K Bickel
Journal:  Exp Clin Psychopharmacol       Date:  1999-11       Impact factor: 3.157

Review 3.  WHO Framework Convention on Tobacco Control: development of an evidence based global public health treaty.

Authors:  Kenji Shibuya; Christina Ciecierski; Emmanuel Guindon; Douglas W Bettcher; David B Evans; Christopher J L Murray
Journal:  BMJ       Date:  2003-07-19

4.  Effectiveness of tax and price policies in tobacco control.

Authors:  Frank J Chaloupka; Kurt Straif; Maria E Leon
Journal:  Tob Control       Date:  2010-11-29       Impact factor: 7.552

5.  Excise, electronic cigarettes and nicotine reduction to reduce smoking prevalence in New Zealand by 2025.

Authors:  Murray Laugesen; Randolph C Grace
Journal:  N Z Med J       Date:  2015-08-21

6.  Relative reinforcing efficacy of alcohol among college student drinkers.

Authors:  James G Murphy; James MacKillop
Journal:  Exp Clin Psychopharmacol       Date:  2006-05       Impact factor: 3.157

7.  Further validation of a cigarette purchase task for assessing the relative reinforcing efficacy of nicotine in college smokers.

Authors:  James MacKillop; James G Murphy; Lara A Ray; Daniel T A Eisenberg; Stephen A Lisman; J Koji Lum; David S Wilson
Journal:  Exp Clin Psychopharmacol       Date:  2008-02       Impact factor: 3.157

8.  Establishing a nicotine threshold for addiction. The implications for tobacco regulation.

Authors:  N L Benowitz; J E Henningfield
Journal:  N Engl J Med       Date:  1994-07-14       Impact factor: 91.245

9.  Validity of a demand curve measure of nicotine reinforcement with adolescent smokers.

Authors:  James G Murphy; James MacKillop; Jennifer W Tidey; Linda A Brazil; Suzanne M Colby
Journal:  Drug Alcohol Depend       Date:  2010-09-15       Impact factor: 4.492

10.  Reduced nicotine content cigarettes, e-cigarettes and the cigarette end game.

Authors:  Neal L Benowitz; Eric C Donny; Dorothy K Hatsukami
Journal:  Addiction       Date:  2016-08-23       Impact factor: 6.526

View more
  33 in total

1.  Young adult dual combusted cigarette and e-cigarette users' anticipated responses to a nicotine reduction policy and menthol ban in combusted cigarettes.

Authors:  Lauren R Pacek; Jason A Oliver; Maggie M Sweitzer; F Joseph McClernon
Journal:  Drug Alcohol Depend       Date:  2018-10-26       Impact factor: 4.492

2.  Comparing participant estimated demand intensity on the cigarette Purchase Task to consumption when usual-brand cigarettes were provided free.

Authors:  Tyler D Nighbor; Anthony J Barrows; Janice Y Bunn; Michael J DeSarno; Anthony C Oliver; Sulamunn R M Coleman; Danielle R Davis; Joanna M Streck; Ellaina N Reed; Derek D Reed; Stephen T Higgins
Journal:  Prev Med       Date:  2020-07-24       Impact factor: 4.018

3.  Impact of E-cigarette Sampling on Cigarette Dependence and Reinforcement Value.

Authors:  Tracy T Smith; Amy E Wahlquist; Bryan W Heckman; K Michael Cummings; Matthew J Carpenter
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

4.  Nicotine reduction does not alter essential value of nicotine or reduce cue-induced reinstatement of nicotine seeking.

Authors:  Gregory L Powell; Joshua S Beckmann; Julie A Marusich; Cassandra D Gipson
Journal:  Drug Alcohol Depend       Date:  2020-04-25       Impact factor: 4.492

5.  Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders.

Authors:  Cara M Murphy; James MacKillop; Rosemarie A Martin; Jennifer W Tidey; Suzanne M Colby; Damaris J Rohsenow
Journal:  Psychopharmacology (Berl)       Date:  2017-05-13       Impact factor: 4.530

6.  Brief Assessment of Cigarette Demand (BACD): Initial development and correlational results in adults and adolescents.

Authors:  Cara M Murphy; Rachel N Cassidy; Rosemarie A Martin; Jennifer W Tidey; James Mackillop; Damaris J Rohsenow
Journal:  Exp Clin Psychopharmacol       Date:  2019-03-21       Impact factor: 3.157

7.  Initial Development of an E-cigarette Purchase Task: A Mixed Methods Study.

Authors:  Rachel N Cassidy; Jennifer W Tidey; Suzanne M Colby; Victoria Long; Stephen T Higgins
Journal:  Tob Regul Sci       Date:  2017-04

8.  Behavioral Economic Purchase Tasks to Estimate Demand for Novel Nicotine/tobacco Products and Prospectively Predict Future Use: Evidence From The Netherlands.

Authors:  Bryan W Heckman; K Michael Cummings; Georges J Nahas; Marc C Willemsen; Richard J O'Connor; Ron Borland; Alexander A Hirsch; Warren K Bickel; Matthew J Carpenter
Journal:  Nicotine Tob Res       Date:  2019-05-21       Impact factor: 4.244

9.  Randomized Trial of Low-Nicotine Cigarettes and Transdermal Nicotine.

Authors:  Tracy T Smith; Joseph S Koopmeiners; Katelyn M Tessier; Esa M Davis; Cynthia A Conklin; Rachel L Denlinger-Apte; Tonya Lane; Sharon E Murphy; Jennifer W Tidey; Dorothy K Hatsukami; Eric C Donny
Journal:  Am J Prev Med       Date:  2019-10       Impact factor: 5.043

Review 10.  Advances in smoking cessation pharmacotherapy: Non-nicotinic approaches in animal models.

Authors:  Lauren C Smith; Olivier George
Journal:  Neuropharmacology       Date:  2020-08-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.